348 related articles for article (PubMed ID: 12819907)
1. Sulphonylurea action revisited: the post-cloning era.
Gribble FM; Reimann F
Diabetologia; 2003 Jul; 46(7):875-91. PubMed ID: 12819907
[TBL] [Abstract][Full Text] [Related]
2. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.
Gribble FM; Reimann F
J Diabetes Complications; 2003; 17(2 Suppl):11-5. PubMed ID: 12623163
[TBL] [Abstract][Full Text] [Related]
3. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Leibowitz G; Cerasi E
Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels.
Ashcroft FM; Gribble FM
J Diabetes Complications; 2000; 14(4):192-6. PubMed ID: 11004427
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of sulphonylurea derivatives.
Smits P; Bijlstra PJ; Russel FG; Lutterman JA; Thien T
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S55-9. PubMed ID: 8864641
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Profile of U-37883A, a Channel Blocker of Smooth Muscle-Type ATP-Sensitive K Channels.
Teramoto N
Cardiovasc Drug Rev; 2006; 24(1):25-32. PubMed ID: 16939631
[TBL] [Abstract][Full Text] [Related]
7. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.
Song DK; Ashcroft FM
Br J Pharmacol; 2001 May; 133(1):193-9. PubMed ID: 11325810
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of action of peroral antidiabetics. Sulfonylurea preparations block the ATP-dependent potassium channels].
Larsson O; Kindmark H; Bränström R; Berggren PO
Lakartidningen; 1997 Nov; 94(48):4473-7. PubMed ID: 9424548
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of ATP-dependent potassium channels.
Ligtenberg JJ; van Haeften TW; Links TP; Smit AJ; Reitsma WD
Neth J Med; 1995 Nov; 47(5):241-51. PubMed ID: 8544897
[TBL] [Abstract][Full Text] [Related]
10. Controversies in management of diabetes in patients with coronary heart disease.
Abdella NA
Med Princ Pract; 2002; 11 Suppl 2():69-74. PubMed ID: 12444313
[TBL] [Abstract][Full Text] [Related]
11. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
[TBL] [Abstract][Full Text] [Related]
12. [ATP-sensitive potassium channels and substances affecting them].
Pospísilová Y
Vnitr Lek; 1998 Jul; 44(7):435-8. PubMed ID: 9748883
[TBL] [Abstract][Full Text] [Related]
13. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.
Reimann F; Proks P; Ashcroft FM
Br J Pharmacol; 2001 Apr; 132(7):1542-8. PubMed ID: 11264248
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
Smits P; Thien T
Diabetologia; 1995 Jan; 38(1):116-21. PubMed ID: 7744216
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic agents that target ATP-sensitive potassium channels.
Rubaiy HN
Acta Pharm; 2016 Mar; 66(1):23-34. PubMed ID: 27029082
[TBL] [Abstract][Full Text] [Related]
16. Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus.
Grunberger G
Drug Saf; 1993 Oct; 9(4):249-53. PubMed ID: 8260118
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ATP-sensitive K+ channels by taurine through a benzamido-binding site on sulfonylurea receptor 1.
Park EJ; Bae JH; Kim SY; Lim JG; Baek WK; Kwon TK; Suh SI; Park JW; Lee IK; Ashcroft FM; Song DK
Biochem Pharmacol; 2004 Mar; 67(6):1089-96. PubMed ID: 15006545
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
Flechtner I; de Lonlay P; Polak M
Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
Löffler C; Quast U
Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
[TBL] [Abstract][Full Text] [Related]
20. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells.
Lawrence CL; Proks P; Rodrigo GC; Jones P; Hayabuchi Y; Standen NB; Ashcroft FM
Diabetologia; 2001 Aug; 44(8):1019-25. PubMed ID: 11484080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
